BioSpace News Archive

Lantern Pharma’s A.I. Platform, RADR ® Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines.

Skye Bioscience, Inc. is pleased to announce the appointment of Dr. Annalisa Jenkins, MBBS, FRCP, to the Company’s Board of Directors.

Phagenesis, a pioneering UK company which has developed a revolutionary neurostimulation system to treat swallowing dysfunction, has closed a $42M Series D financing all equity investment round.

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2023 and provided an update on key operational initiatives.

Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF) announced today positive preclinical data showing SAT-3247 can improve skeletal muscle function in multiple mouse models of muscle degeneration.

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for arimoclomol, an investigational orally delivered, first-in-class treatment for Niemann-Pick disease type C (NPC).

Eilean Therapeutics LLC announced the acquisition of Ness Therapeutics Inc in an all-equity transaction.

4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, announced the appointment of Kimberly Lee, D.O. as Chief Business Officer and member of the executive management team.

QurAlis Corporation today announced preclinical data that showed the company’s UNC13A splice-switching antisense oligonucleotides (ASOs) modulate UNC13A splicing and restore normal synaptic activities in ALS and FTD.

Verona Pharma plc, announces Mr. Andrew Fisher has joined the Company as General Counsel, and member of the Executive Management Team.